Invesco Ltd. - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 158 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.9%.

Quarter-by-quarter ownership
Invesco Ltd. ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$819,239
+3.0%
107,090
+0.5%
0.00%
Q2 2023$795,630
+0.1%
106,510
-10.7%
0.00%
Q1 2023$795,164
+131.1%
119,215
+167.2%
0.00%
Q4 2022$344,020
-28.0%
44,620
-0.7%
0.00%
Q3 2022$478,000
+32.4%
44,952
+1.5%
0.00%
Q2 2022$361,000
+12.8%
44,283
-0.8%
0.00%
Q1 2022$320,000
-57.0%
44,633
+2.7%
0.00%
Q4 2021$745,000
+263.4%
43,473
+674.6%
0.00%
Q2 2021$205,0005,6120.00%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q1 2023
NameSharesValueWeighting ↓
Obvious Management Services, L.L.C. 3,985,087$42,401,000100.00%
Two Sigma Ventures, LP 903,400$9,612,000100.00%
DCVC Opportunity Fund II GP, LLC 3,951,141$42,040,00054.37%
Data Collective IV GP, LLC 5,941,120$63,214,00049.97%
MIC Capital Management UK LLP 8,451,758$89,927,00016.21%
MV Management XI, L.L.C. 1,971,908$20,981,00015.20%
ArchPoint Investors 1,116,126$11,876,0004.85%
HARVARD MANAGEMENT CO INC 1,509,254$16,058,0002.00%
PLATINUM INVESTMENT MANAGEMENT LTD 2,251,971$23,961,0001.00%
Duquesne Family Office 1,385,950$14,747,0000.84%
View complete list of RECURSION PHARMACEUTICALS IN shareholders